Fidelis Capital Partners’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.2M Buy
45,766
+779
+2% +$181K 0.8% 27
2025
Q4
$9.31M Buy
44,987
+7,641
+20% +$1.51M 0.68% 28
2025
Q3
$6.92M Buy
37,346
+4,615
+14% +$791K 0.54% 36
2025
Q2
$5.58M Buy
32,731
+122
+0.4% +$18.8K 0.51% 37
2025
Q1
$5.04M Buy
32,609
+2,636
+9% +$412K 0.54% 38
2024
Q4
$4.55M Buy
29,973
+1,213
+4% +$188K 0.46% 48
2024
Q3
$4.77M Buy
28,760
+2,155
+8% +$343K 0.57% 32
2024
Q2
$4.23M Buy
26,605
+2,460
+10% +$366K 0.6% 34
2024
Q1
$3.82M Buy
24,145
+6,938
+40% +$1.1M 0.58% 34
2023
Q4
$2.7M Buy
17,207
+4,026
+31% +$617K 0.6% 35
2023
Q3
$2.05M Buy
13,181
+1,992
+18% +$329K 0.7% 28
2023
Q2
$1.85M Buy
11,189
+369
+3% +$59.6K 0.68% 33
2023
Q1
$1.76M Buy
10,820
+6,413
+146% +$1.04M 0.75% 26
2022
Q4
$774K Buy
+4,407
New +$761K 0.91% 27

Other funds holding JNJ

Fidelis Capital Partners's JNJ Position: Q1 2026 in Review

Fidelis Capital Partners increased its Johnson & Johnson (JNJ) stake by 1.7% in Q1 2026, buying an estimated $181K and bringing the position to 45,766 shares worth $11.2M. The position accounts for 0.8% of the portfolio, ranked #27.

Fidelis Capital Partners first reported a position in JNJ in Q4 2022 and has held it in 14 quarters since. 4,616 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Fidelis Capital Partners held 45,766 shares of Johnson & Johnson worth $11.2M as of Q1 2026.
  • Fidelis Capital Partners bought 779 Johnson & Johnson shares in Q1 2026, an estimated $181K.
  • Johnson & Johnson made up 0.8% of Fidelis Capital Partners's portfolio in Q1 2026, its #27 holding.
  • Fidelis Capital Partners first reported a position in Johnson & Johnson in Q4 2022 and has held it in 14 quarters since.
  • 4,616 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.